Possible Treatment For Antibiotic Resistant Bacteria Identified

Specifically engineered liposomes can be used to prevent bacterial toxins from killing human cells.
Specifically engineered liposomes can be used to prevent
bacterial toxins from killing human cells.  (Image source)
A new study, published in Nature Biotechnology, showed that specially engineered lipid (fat) bodies, called liposomes, can be used to prevent bacterial toxins from killing human cells. This could prevent unnecessary deaths from diseases such as pneumonia and sepsis. The treatment is a valuable alternative to current medications, particularly for infections that have become resistant to antibiotics.
 
The bacterial toxins, produced by major human pathogens such as Streptococcus pneumonia, Streptococcus pyogenes and Methicillin Resistant Staphlycoccus aureus (MRSA) were neutralised as they bound to the liposomes instead of human cells.
 
Liposomes are already licensed for medical use as carriers for drug delivery and are nontoxic to humans. The research team has now shown that they can also be used therapeutically, either alone or in conjunction with antibiotics to combat bacterial infections and to minimize toxin-induced tissue damage and inflammation.
 
This treatment can be used for antibiotic resistant bacteria as well as for the treatment of antibiotic-sensitive bacteria, to prevent the release of toxins that leads to deterioration of the clinical condition of the patient.